YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling

Qimin Zhou1,2, Monika Bauden2, Roland Andersson2, Dingyuan Hu2, György Marko-Varga3, Jianfeng Xu4, Agata Sasor5, Hua Dai6, Krzysztof Pawłowski7,8, Katarzyna Said Hilmersson2, Xi Chen1 and Daniel Ansari2*

Abstract

Background: Pancreatic cancer is a major cause of cancer-related mortality. The identification of effective biomarkers is essential in order to improve management of the disease. Yes-associated protein 1 (YAP1) is a downstream effector of the Hippo pathway, a signal transduction system implicated in tissue repair and regeneration, as well as tumorigenesis. Here we evaluate the biomarker potential of YAP1 in pancreatic cancer tissue.

Methods: YAP1 was selected as a possible biomarker for pancreatic cancer from global protein sequencing of fresh frozen pancreatic cancer tissue samples and normal pancreas controls. The prognostic utility of YAP1 was evaluated using mRNA expression data from 176 pancreatic cancer patients in The Cancer Genome Atlas (TCGA), as well as protein expression data from immunohistochemistry analysis of a local tissue microarray (TMA) cohort comprising 140 pancreatic cancer patients. Ingenuity Pathway Analysis was applied to outline the interaction network for YAP1 in connection to the pancreatic tumor microenvironment. The expression of YAP1 target gene products was evaluated after treatment of the pancreatic cancer cell line Panc-1 with three substances interrupting YAP–TEAD interaction, including Super-TDU, Verteporfin and CA3.

Results: Mass spectrometry based proteomics showed that YAP1 is the top upregulated protein in pancreatic cancer tissue when compared to normal controls (log2 fold change 6.4; p = 5E−06). Prognostic analysis of YAP1 demonstrated a significant correlation between mRNA expression level data and reduced overall survival (p = 0.001). In addition, TMA and immunohistochemistry analysis suggested that YAP1 protein expression is an independent predictor of poor overall survival [hazard ratio (HR) 1.870, 95% confidence interval (CI) 1.224–2.855, p = 0.004], as well as reduced disease-free survival (HR 1.950, 95% CI 1.299–2.927, p = 0.001). Bioinformatic analyses coupled with in vitro assays indicated that YAP1 is involved in the transcriptional control of target genes, associated with extracellular matrix remodeling, which could be modified by selected substances disrupting the YAP1-TEAD interaction.

Conclusions: Our findings indicate that YAP1 is an important prognostic biomarker for pancreatic cancer and may play a regulatory role in the remodeling of the extracellular matrix.

Keywords: Pancreatic cancer, YAP1, Transcriptomics, Proteomics, Prognosis, Extracellular matrix remodeling, Cancer
the second leading cause by 2030 [2]. Multiple factors, such as late diagnosis and resistance to conventional therapies, contribute to the overall poor prognosis.

The ability to identify subgroups of patients that may benefit from specific clinical management is considered central to modern precision oncology. For that purpose, large-scale genomic studies have been performed to determine molecular subtypes of pancreatic cancer requiring individualized treatments [3–6]. Such studies have massively increased our understanding of pancreatic cancer at the molecular level.

Proteomics is a valuable complement to genetic studies. Mass spectrometry (MS)-based proteomics profiling of patient-derived samples has been suggested as an effective approach for the discovery of biomarkers and detection of suitable therapeutic targets in many cancers [7–10].

Yes-associated protein 1 (YAP1) is a downstream effector of the Hippo signaling pathway, which is involved in tissue repair and regeneration, as well as tumorigenesis. Activation of the Hippo pathway leads to inactivation of YAP1 by cytoplasmic retention or proteolytic degradation [11, 12]. YAP1 in its active form, on the other hand, functions as a transcriptional co-activator predominantly mediated by an interaction with TEAD transcription factors [13]. Active YAP1 is also recognized as a potent oncogene closely linked to the progression of several cancer types [14, 15]. However, the role of the YAP1-TEAD interaction in regulating the expression of target genes in pancreatic cancer has not been completely explored.

In a previous study [10], we identified YAP1 as a differentially expressed protein between pancreatic cancer and normal controls using MS-based proteomics profiling. In the present study, we investigate the prognostic utility and the biological significance of YAP1 in pancreatic cancer using large and clinically well-annotated cohorts, complemented by bioinformatics and in vitro experimental analyses.

**Materials and methods**

**Patient samples**

For the MS-based proteomics, fresh frozen pancreatic cancer tissues (n = 10) were collected from patients with pancreatic ductal adenocarcinoma undergoing pancreaticoduodenectomy between July 2013 and April 2015 at the Department of Surgery, Skåne University Hospital, Lund, Sweden. Written informed consent was obtained from the patients included in the study. Age and gender-matched, fresh frozen, normal pancreatic biopsies (n = 10) were assessed from organ donors and obtained from the national consortium Excellence of Diabetes Research in Sweden and Lund University Diabetes center (LUDC).

The immunohistochemical (IHC) target verification was performed using tissue microarrays (TMA) from archival formalin-fixed paraffin-embedded (FFPE) resection specimens from 140 patients with pancreatic ductal adenocarcinoma who underwent curative intent pancreatic surgery from 1995 to 2017 at Skåne University Hospital, Lund and Malmö, Sweden.

All samples were histopathologically verified and selected by a specialized surgical pathologist prior to analysis. Ethical permission for the study was granted by the Ethical Committee at Lund University (Ref 2010/684, 2012/661, 2015/266, 2017/320). The REMARK guidelines were followed where applicable [16].

**MS-based proteomics**

Sample processing and LC–MS/MS analysis were performed as reported previously [10]. Briefly, proteins extracted from fresh frozen pancreas specimens were reduced, alkylated and digested into peptides using Lys-C and trypsin. The peptides were analyzed using a high-performance liquid chromatography system, EASY-nLC 1000 connected to Q Exactive quadrupole-Orbitrap mass spectrometer equipped with a nanospray ion source (Thermo-Fisher Scientific, Bremen, Germany). To identify the detected proteins, the acquired MS/MS data were managed using Proteome Discoverer software, version 1.4 (Thermo Fisher).

**mRNA expression data**

Publicly available transcriptomics data were retrieved from 176 pancreatic cancer patients from The Cancer Genome Atlas (TCGA) [17–19]. RNA-seq data were analyzed as the number of Fragments Per Kilobase of exon per Million reads (FPKM).

**Tissue microarray**

The TMA was constructed from FFPE pancreatic tumors by a trained biomedical technician using an automated tissue array device (Minicores® 3, Alphelys, Plaisir, France). A set of 4 cores with a diameter of 2 mm were extracted from each specimen and fixed into a new paraffin block. The completed blocks were then sectioned into 3 μm thick sections and mounted on glass slides.

**Immunohistochemistry**

IHC analysis was performed as described previously [20]. Briefly, deparaffinization, rehydration and antigen-retrieval were performed using the automated PT Link system (Dako, Agilent Technologies, Glostrup, Denmark). TMA-slides were then incubated with monoclonal rabbit anti-human primary antibody against YAP1.
(dilution 1:200; Cell Signaling) followed by biotinylated goat anti-rabbit secondary antibody (dilution 1:200; Vector Laboratories, Burlingame, CA). Avidin–biotin–peroxidase complex (Vectastain Elite ABC-HRP Kit, Vector Laboratories, Burlingame, CA) was used for signal amplification. The color was developed using chromogen diaminobenzidine (DAB) (Vector Laboratories). The nuclei were colored with hematoxylin. The immunostaining was evaluated by three independent pathologists, blinded to clinical information. H-score was applied as a semiquantitative approach [21, 22]. The intensity of YAP1 staining was scored as [0] (negative), [1+] (weak), [2+] (moderate), or [3+] (strong) and the percentage of cells at each staining intensity level was recorded. The H-scores were calculated by following formula:

\[
H\text{-score} = 0 \times (\% \text{ cells } [0]) + 1 \times (\% \text{ cells } [1]) + 2 \times (\% \text{ cells } [2]) + 3 \times (\% \text{ cells } [3]).
\]

**Bioinformatics**

Ingenuity Pathway Analysis software (IPA, Qiagen, Inc. Redwood City, CA, USA) was used for bioinformatic analysis of networks involving the biological relationship between YAP1 and pancreatic cancer. A network involving all direct interactors of these proteins was built and analyzed for pathway enrichment and functional annotations.

**Cell culture**

The patient derived pancreatic cancer cell line Panc-1 (ATCC-LGC Standards, Manassas, VA, USA) was used for the in vitro experiments. The cells were maintained in DMEM supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin and kept in a humified atmosphere, in 5% CO₂ at 37 °C. Prior experiment, the cells were observed using phase contrast microscope to ensure the condition of the cells including morphological characteristics and vitality.

**Immunofluorescence based Cellomics**

To assert the YAP1 expression profile, the cells were seeded in 6-well plates with the density of fifty thousand cells per well. After 48 h, the cells were fixed with 4% paraformaldehyde (Histolab, Västra Frölunda, Sweden) and stained with primary rabbit anti-human YAP1 (dilution 1: 250, Cell Signaling) followed by Alexa Fluor 488 conjugated donkey-anti-rabbit secondary antibody (dilution 1:200, Invitrogen, USA). The nucleus was marked using DAPI (NucBlue®, Molecular probes, Life technologies, USA). Cellomics ArrayScan platform VT1 HCS (ThermoScientific, Rockford, IL, USA) reader connected to Bioapplication software was thereafter used for image processing.

In each well, a cell population consisting of two thousand cells was analysed using multiparameter fluorescent microscopic imaging system designed for high content screening. The processed data obtained from automatically acquired images were quantified as fluorescence intensity for the selected channel (Alexa 488). The accessed images were visualized using automated fluorescence microscopy.

**YAP1 target gene expression**

To evaluate the expression of selected YAP1 target genes, the cells were seeded in 6-well plates with a concentration of thirty thousand cells per well. After one cell cycle, the cells were incubated with a maximal tolerable dose of three substances interrupting YAP–TEAD interaction; Super-TDU (500 nM), Verteporfin (100 nM) and CA3 (100 nM) or complete medium. After 48 h, the cell lysates and conditioned medium from respective well and plate were collected. All experiments were executed in triplicates. Expression levels of YAP1 targets genes, including amphiregulin (AREG), connective tissue growth factor (CTGF), cysteine-rich angiogenic inducer 61 (CYR61), fibroblast growth factor 1 (FGF1) and mesothelin (MSLN), were selected from the Ingenuity Pathway Analysis and measured in each sample using enzyme-linked immunosorbent assay (ELISA). 100 µg protein from respective sample was analyzed in each assay according to the manufacturer’s instructions. AREG, CTGF, CYR61, FGF1 were purchased from Nordic Biosite AB, Täby, SE and MSLN from Biolegend, San Diego, CA, USA.

**Statistical analysis**

The correlation between YAP1 expression levels and clinicopathological parameters was estimated using the Mann–Whitney U test for continuous variables and Fisher’s exact test or χ² for categorical variables. The Kaplan–Meier method was used to model the cumulative probability of overall survival (OS) and disease-free survival (DFS) and statistical differences were assessed using the log-rank test. Univariable and multivariable survival analysis were also performed using Cox proportional hazards regression modeling.

One-way ANOVA parametric test was applied to compare the concentrations of secreted YAP target genes measured in condition medium obtained from Panc-1 cells subjected to three substances interrupting YAP1 transcriptional activity or untreated cells.

Statistical evaluation was conducted with SPSS version 23.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism.
v.8.0.1 (La Jolla, CA, USA). A p-value < 0.05 was considered statistically significant.

Results

YAP1 is the top upregulated protein in pancreatic cancer

Fresh frozen biopsies from pancreatic tumors (n = 10) and healthy pancreatic tissue (n = 10), were analyzed using label-free quantitative proteomics to discover differentially expressed proteins. In total, 4138 proteins were identified, and 2950 proteins were quantified based on one or more unique peptides. 165 candidates were subsequently determined as potential biomarkers for pancreatic cancer, as previously reported [10]. Characterized by six unique peptides, YAP1 was annotated as the top upregulated protein in pancreatic tumor specimens (log2 fold change 6.4; p = 5E−06) (Fig. 1a, b).

mRNA expression levels of YAP1 as a prognostic marker

To assess the prognostic significance of YAP1, we analyzed mRNA expression level data and patient survival based on 176 pancreatic cancer patients included in TCGA (Table 1). The median FPKM value was 19.0, ranging from 0.5 to 46.6. The median FPKM value was used to divide the cohort into a low (FPKM ≤ 19) and a high expression group (FPKM > 19). The Kaplan–Meier plots revealed that high YAP1 mRNA expression was significantly correlated with poorer OS when compared with low mRNA YAP1 expression, as illustrated in Fig. 2 (median survival 17 months vs. 23 months, respectively, p = 0.001).

YAP1 protein expression levels and prognosis

The protein expression levels of YAP1 were analyzed using immunohistochemistry staining on TMA sections constructed from 140 pancreatic tumors. The antibody

Table 1 Characteristics of the TCGA cohort (n = 176)

| Variable                          | N = 176 |
|----------------------------------|---------|
| Median age (range), years        | 65 (35–88) |
| Female gender                    | 50 (45.5%) |
| AJCC-stage                       |         |
| I                                | 21 (11.9%) |
| II                               | 145 (82.4%) |
| III                              | 3 (1.7%) |
| IV                               | 4 (2.3%) |
| Unknown                          | 3 (1.7%) |
| Median FPKM (range)              | 19.0 (0.5-46.6) |
staining specific for YAP1 was detected in the nucleus or in the nucleus and cytoplasm of tumor cells. The median H-score was 170 (range, 59–289). Based on the median H-score (170), a low (H-score ≤ 170) and a high expression group (H-score > 170) were created (Fig. 3a). No significant differences in clinicopathological features were identified between high and low YAP1 expression groups (Table 2).

Kaplan–Meier analysis revealed that high YAP1 protein expression was significantly correlated with shorter OS when compared with low YAP1 protein expression (median survival, 17.9 vs. 34.3 months, respectively, \( p = 0.001 \), log-rank test; Fig. 3b). Furthermore, patients exhibiting high YAP1 protein expression had significantly reduced DFS when compared to the low YAP1 protein expression group (median DFS, 10.7 vs. 17.5 months, respectively, \( p = 0.005 \), log-rank test; Fig. 3c).

The univariable Cox regression analysis of OS identified smoking history (\( p = 0.04 \)), symptoms at diagnosis (\( p = 0.05 \)), histopathological grade (\( p = 0.03 \)), and high expression of YAP1 (\( p = 0.001 \)) as factors associated with shorter OS. In multivariable Cox regression analysis, high YAP1 protein expression was identified as an independent risk factor for poor OS (hazard ratio (HR) 1.870, 95% confidence interval (CI) 1.224–2.855, \( p = 0.004 \)). Moreover, univariable Cox regression analysis of DFS determined histopathological grade (\( p = 0.028 \)), resection margin ≥ R1 (\( p = 0.028 \)), and high expression of YAP1 (\( p = 0.006 \)) as factors associated with decreased DFS. Multivariable Cox regression analysis confirmed the results, indicating that high YAP1 protein expression is an independent risk factor for reduced DFS (HR 1.950, 95% CI 1.299–2.927, \( p = 0.001 \)) (Table 3).

We thus interpret that YAP1 may function as a marker for poor prognosis and disease relapse in pancreatic cancer patients.

**YAP1 is connected to mediators promoting remodeling of the extracellular matrix**

Subsequently, we explored the biological background of the obtained results with the aim to identify the most significant networks and relationships associated with YAP1 expression in pancreatic cancer. Bioinformatic analysis using the IPA software revealed that YAP1 is

---

**Fig. 3** Immunohistochemical analysis of YAP1 protein expression in the tissue microarray cohort. **a** Representative images of YAP1 immunostaining in low and high expression groups using the median H-score (170) as cut-off. **b** Kaplan–Meier survival curves for overall survival stratified by YAP1 protein expression. **c** Kaplan–Meier survival curves for disease-free survival stratified by YAP1 protein expression.
Table 2  Characteristics of the TMA cohort (n = 140)

| Variable                      | N    | All patients (n = 140) | Low YAP1 protein expression (n = 70) | High YAP1 protein expression (n = 70) | p       |
|-------------------------------|------|------------------------|-------------------------------------|--------------------------------------|---------|
| Age > 65 years                | 140  | 93 (66.4)              | 48 (68.6)                           | 45 (64.3)                            | 0.721   |
| Female gender                 | 140  | 66 (47.1)              | 35 (50)                             | 31 (44.3)                            | 0.612   |
| BMI > 25 kg/m²                | 132  | 57 (43.2)              | 32 (47.1)                           | 25 (39.1)                            | 0.383   |
| Smoking history               | 139  | 67 (48.2)              | 28 (40.6)                           | 39 (55.7)                            | 0.09    |
| Diabetes mellitus             | 139  | 33 (23.7)              | 19 (27.1)                           | 14 (20.3)                            | 0.426   |
| Symptoms at diagnosis         | 136  | 131 (96.3)             | 68 (100)                            | 63 (92.6)                            | 0.058   |
| Tumor location (head)         | 140  | 117 (83.6)             | 62 (88.6)                           | 55 (78.6)                            | 0.17    |
| Tumor size > 2 cm             | 139  | 117 (84.2)             | 60 (87)                             | 57 (81.4)                            | 0.487   |
| T-stage ≥ T2                  | 139  | 121 (87.1)             | 60 (87)                             | 61 (87.1)                            | 1       |
| N-stage ≥ N1                  | 138  | 104 (75.4)             | 53 (76.8)                           | 51 (73.9)                            | 0.844   |
| AJCC-stage ≥ II               | 138  | 112 (81.2)             | 56 (81.2)                           | 56 (81.2)                            | 1       |
| Histological grade ≥ 3        | 138  | 83 (60.1)              | 38 (55.9)                           | 45 (64.3)                            | 0.385   |
| Positive resection margin     | 139  | 55 (39.6)              | 28 (40.6)                           | 27 (38.6)                            | 0.863   |
| Adjuvant chemotherapy         | 135  | 113 (83.7)             | 60 (87)                             | 53 (80.3)                            | 0.355   |
| Recurrence of disease         | 127  | 103 (81.1)             | 51 (79.7)                           | 52 (82.5)                            | 0.821   |

N, number of non-missing values. Qualitative data are expressed as n (%)

AJCC American Joint Committee on Cancer, BMI body mass index, N-stage nodal stage, T-stage tumor stage

Table 3  Univariable and multivariable Cox regression analysis in the TMA cohort (n = 140)

| Variable                      | OS          | DFS          |
|-------------------------------|-------------|--------------|
|                               | Univariable HR (95% CI) | p        | Multivariate HR (95% CI) | p       | Univariable HR (95% CI) | p        | Multivariate HR (95% CI) | p       |
| Age (> 65)                    | 0.994 (0.658–1.501) | 0.977      | 0.760 (0.506–1.144) | 0.189   |
| Female gender                 | 0.825 (0.557–1.221) | 0.336      | 0.675 (0.453–1.005) | 0.053   |
| BMI (> 25 kg/m²)              | 1.250 (0.832–1.876) | 0.283      | 1.372 (0.913–2.061) | 0.128   |
| Smoking history               | 1.510 (1.019–2.239) | 0.04*      | 1.319 (0.868–2.003) | 0.195   |
| Diabetes                      | 0.782 (0.479–1.277) | 0.326      | 0.927 (0.567–1.515) | 0.762   |
| Symptoms at diagnosis         | 0.363 (0.132–1.000) | 0.05*      | 0.548 (0.193–1.559) | 0.260   |
| Tumor location (head)         | 0.658 (0.390–1.112) | 0.118      | 1.143 (0.625–2.092) | 0.664   |
| Tumor size (> 2 cm)           | 1.090 (0.653–1.819) | 0.741      | 1.215 (0.710–2.079) | 0.478   |
| N-stage (> N1)                | 1.152 (0.672–1.973) | 0.607      | 1.429 (0.795–2.571) | 0.233   |
| AJCC-stage (> II)             | 1.474 (0.924–2.352) | 0.104      | 1.316 (0.829–2.088) | 0.244   |
| Histological grade (> 3)      | 1.426 (0.855–2.379) | 0.174      | 1.345 (0.814–2.222) | 0.248   |
| Resection margin (≥ R1)       | 1.580 (1.045–2.390) | 0.03*      | 1.728 (1.123–2.657) | 0.013*  |
| Adjuvant chemotherapy         | 1.388 (0.926–2.080) | 0.112      | 1.585 (1.050–2.413) | 0.128*  |
| YAP1 protein expression (High)| 1.917 (1.288–2.854) | 0.001*     | 1.870 (1.224–2.855) | 0.004*  |

Variables with p ≤ 0.05 were marked with asterisk (*), variables with p ≤ 0.05 in univariable analysis were included in multivariable analysis

AJCC American Joint Committee on Cancer, BMI body mass index, CI confidence interval, DFS disease free survival, HR hazard ratio, N-stage nodal stage, OS overall survival, T-stage tumor stage
directly related to proteins involved in mechanotransduction, such as PATJ and PIEZO1, and the cytokine EDN1 (Fig. 4). Tight junction signalling proteins related to YAP1 include CTNNA1, MPDZMP5, OCLN, PATJ, and TJP2. Epithelial adherens junction signalling proteins related to YAP1 include CDH1, CTNNA1, CTNNA2, EGFR, FGF1, PARD3, and ZYX. Examples of secreted proteins involved in creating a pro-fibrotic microenvironment include AREG, CTGF, CYR61, FGF1, and MSLN and these YAP1 target genes were chosen for further in vitro confirmation.

**YAP1 participates in the transcription of target genes involved in profibrotic tumor microenvironment**

Next, we investigated co-transcriptional activity of YAP1 in synthesis of secreted proteins associated with remodeling of the tumor microenvironment in pancreatic cancer. First, Panc-1 cells were cultured under standard conditions to assess the expression levels of proteins ascertained by the IPA analysis. All investigated proteins, AREG, CTGF, CYR61, FGF1, and MSLN were considered as low abundant and detected in low concentrations (pg/ml) in lysates of Panc-1 cells cultured under standard conditions. As presented in Fig. 5b, the expression levels corresponded to at a maximum 0.2% of the total cellular protein amount.

Next, the collected conditioned medium from the Panc-1 cells was analyzed for the presence of selected proteins. AREG, CTGF, CYR61, and MSLN were identified and the secretion pattern was further investigated. Panc-1 cells were subjected to substances inhibiting YAP1 transcriptional activity and the concentrations of the determined secreted proteins were measured. Levels of secreted AREG, CTGF, CYR61, and MSLN were significantly lower (p = 0.0001) or undetectable in conditioned medium after the treatment (Fig. 5c). Based on the obtained results, we suggest that YAP1 is involved in the transcription of genes associated with remodeling of the pancreatic tumor microenvironment.

**Discussion**

In this transcriptome- and proteome-based study, we identified YAP1 as an indicator of poor OS and DFS in patients with pancreatic cancer.

The American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) classification system is currently the gold standard for pancreatic cancer prognostication [23]. However, the AJCC TNM system is only concerned with the anatomical extent of the disease though patients within the same stage may exhibit different outcomes [24]. Such evaluation may lead to either over- or undertreatment. Improved staging systems, considering molecular factors are necessary in order to enhance individual prognostication and utilization of precision therapies.

The prognostic significance of YAP1 protein expression has only been evaluated in one previous small study by Allende et al. [25]. However, YAP1 protein expression did not reach statistical significance in their Kaplan–Meier analysis, likely due to the small cohort size (64 patients). Only when conducting subgroup analyses, stratifying...
survival into groups of patients surviving more than or less than 30 months, it was shown that patients with high YAP1 expression had worse survival. Therefore, to clarify the prognostic role of YAP1 protein expression in pancreatic cancer, additional studies based on larger cohorts are needed. The TMA/immunohistochemistry analysis based on 140 patients in our study revealed that overexpression of YAP1 is an independent factor for unfavorable outcome and disease recurrence. These findings are in agreement with the public mRNA dataset from the TCGA, which illustrate that high expression of YAP1 significantly correlates with poor survival in pancreatic cancer patients. The agreement between the transcriptome- and proteome-based survival analyses in the present study strengthens the clinical significance of YAP1 as a prognostic variable. However, it is important to note that knowledge about mRNA abundances can only partially predict protein abundances, with a large fraction of the variance also being explained by other factors such as post-transcriptional and translational regulation, as well as protein degradation [26].

To understand the biological role of YAP1 in pancreatic cancer, we performed bioinformatic analyses of protein networks. The results revealed that YAP1 is directly connected to secreted AREG, CTGF, CYR61, FGF1 and MSLN that are involved in fibrosis and other key signaling pathways involved in the tumor-stroma interactions [27–31].

Pancreatic cancer progression is generally associated with a dense fibrotic stroma characterized by an extensive deposition of extracellular matrix components surrounding the cancer cells [32, 33]. The desmoplastic extracellular matrix, mainly produced by activated cancer associated fibroblasts, accounts for up to 80% of entire tumor mass [33]. The fibrotic environment is known to undergo an extensive remodeling connected to the stiffening of tumor tissue. Such stromal reshaping presumably modifies the crosstalk between residual cells within the tumor and directs the tumor progression towards an aggressive phenotype [33–35]. The increased stiffness of matricellular tumor microenvironment also activates YAP1 to further modulate the behavior of cancer cells on the transcriptional level [36, 37].

YAP1 itself, however, lacks DNA-binding activity and requires an interaction with DNA-binding transcription factors such as TEAD to activate target genes [38]. AREG, CTGF and CYR61 account for the most acknowledged target genes for YAP1/TEAD [39–41]. The YAP1/TEAD interactions are also reported to regulate the expression of FGF1 and MSLN [42–44].

We hypothesized that the secreted YAP1/TEAD target gene products contribute to the enhanced fibrotic

**Fig. 5** In vitro analysis of YAP1 and selected target genes in Panc-1 cells. **a** YAP1 protein expression in Panc-1 cells. The image represents an immunofluorescence staining of endogenous YAP1 in Panc-1 cells, plated in 6 well plates and cultivated for 48 h under standard conditions. The arrows indicate an exemplification of YAP1 nuclear accumulation. **b** Concentrations of YAP1 target genes in lysates obtained from Panc-1 cells cultivated under standard conditions. **c** Concentrations of YAP1 target genes in conditioned medium obtained from Panc-1 cells that were subjected to maximal tolerable doses (MTD) of substances blocking the YAP1/TEAD interaction.
reaction and intra-tumoral stiffening which consecutively promote YAP1 transcripational activity. Such paracrine loop would further affect the tumor microenvironment and maintain the aggressive course of the disease.

Using the patient derived pancreatic cancer cell line Panc-1, we evaluated the effect of substances designed to inhibit the YAP1/TEAD mediated gene transcription. We showed that the disruption of YAP1/TEAD complex significantly reduced the presence of the selected YAP1/TEAD target gene products in the conditioned medium. Suppression of YAP1 oncogenic activity with a subsequent modification of the tumor microenvironment may thus be an advantageous approach to control tumor growth and improve prognosis. Although the clinical utilization for such treatment remains to be determined, YAP1 as a biomarker may aid in the individual prognostication of patients diagnosed with pancreatic cancer and the selection of precision therapy.

Conclusions

We demonstrate that YAP1 is an independent prognostic marker associated with recurrence and unfavorable survival in pancreatic cancer. We also show that inhibition of YAP1/TEAD interaction interferes with the expression of AREG, CTGF, CYR61, and MSLN suggesting that YAP1 transcriptional activity may affect the development and persistence of a fibrotic tumor microenvironment. YAP1 is thus considered as a clinically and biologically relevant biomarker derived from pancreatic cancer tissue.

Abbreviations

AJCC: American Joint Committee on Cancer; AREG: Amphiregulin; BMI: Body mass index; CI: Confidence interval; CTGF: Connective tissue growth factor; CYR61: Cysteine-rich angiogenic inducer 61; DFS: Disease-free survival; ELISA: Enzyme-linked immunosorbent assay; FFPE: Formalin-fixed paraffin-embedded; FGF: Fibroblast growth factor 1; FPKM: Fragments per kilobase of exon per million reads; HR: Hazard ratio; IHC: Immunohistochemistry; IPA: Ingenuity Pathway Analysis; MS: Mass spectrometry; MSLN: Mesothelin; OS: Overall survival; TCGA: The Cancer Genome Atlas; TMA: Tissue microarray; TNM: Tumor-node-metastasis; YAP1: Yes-associated protein 1.

Acknowledgements

The mRNA results published here are based upon data generated by the TCGA Research Network (https://www.cancer.gov/tcga) and the Human Protein Atlas program (http://www.proteinatlas.org/pathology). We thank Indira Pia, Aniel Sanchez Puente, Jeovanis Gil valdes and Lazaro Hiram Betancourt for technical support with the proteomics analysis in this manuscript.

Authors’ contributions

QZ and DA conceived the original idea and designed the study with GMV and RA. QZ, MB, JX, AS, DH, XD, KC, KSH and DA collected the data for the study, which were analyzed by QZ, MB and KP. The data interpretation and manuscript drafting were performed by QZ, MB and DA. The manuscript was revised by GMV and RA. All authors reviewed the manuscript. All authors read and approved the final manuscript.

Funding

Open access funding provided by Lund University. This work was supported by the Magnus Bergvall Foundation, the Royal Physiographic Society of Lund, the Tore Nilsson Foundation, the Inga and John Hain Foundation for Medical Research, the Clas Groschinsky Foundation, the Gunnar Nilsson Foundation, the Gyllenstiernska Krapperup Foundation, the Bengt Ihre Foundation, the Emil and Vera Cornell Foundation, The Crawford Foundation, Governmental Funding of Clinical Research within the National Health Service (ALF) and Sweden’s Innovation Agency (Vinnova).

Availability of data and materials

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study was performed in compliance with the Helsinki Declaration on ethical principles for handling human tissue specimens, with all EU and national regulations and requirements. Written informed consent was obtained from participants. Ethical permission for the study was granted by the Ethics Committee at Lund University (Ref 2010/684, 2012/661, 2015/266, 2017/320).

Consent for publication

Consent for publication was obtained from included participants.

Competing interests

The authors declare that they have no competing interests.

Author details

1 The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China. 2 Department of Surgery, Clinical Sciences Lund, Lund University and Skåne University Hospital, 221 85 Lund, Sweden. 3 Clinical Protein Science and Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, Lund, Sweden. 4 Department of Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. 5 Department of Pathology, Skåne University Hospital, Lund, Sweden. 6 Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, China. 7 Department of Experimental Design and Bioinformatics, Warsaw University of Life Sciences, Warsaw, Poland. 8 Department of Translational Medicine, Lund University, Malmö, Sweden.

Received: 10 September 2019 Accepted: 1 February 2020
Published online: 13 February 2020

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.
3. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–6.
4. Collisson EA, Sadanandam A, Olson P, Gabb JW, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500–3.
5. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2011;47:41–72.
6. Moffitt RA, Marayati R, Flate EL, Volmar KE, Locea SG, Hoadley KA, Rashid NLI, Williams LA, Eaton SC, Chung AH, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47:1168–78.
7. Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, Ziegler E, Butzmann L, Gessulat S, Marx H, et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014;509:582–7.
8. Zhou Q, Anderson R, Hu D, Bauden M, Saso A, Bygott T, Pawlowski K, Pla I, Marko-Varga G, Ansari D. Alpha-1-acid glycoprotein 1 is upregulated in
Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz LE, Vessella R, Weitz J, Rabbah N, et al. Gliptican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523:177–82.

Zhou Q, Andersson R, Hu D, Bauden M, Krist T, Sasor A, Pavlovski K, Pla I, Hilmersson KS, Zhou M, et al. Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue. EbioMedicine. 2019;43:282–94.

Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogenic YAP. J Biol Chem. 2008;283:5496–509.

Maugeri-Sacca M, De Maria R. The Hippo pathway in normal development and cancer. Pharmacol Ther. 2018;186:60–72.

Stein C, Bardet AF, Roma G, Bergling S, Clay L, Ruchti A, Agarinas C, Schmelzle T, Bouvmeester T, Schueller D, Baurer A. YAP1 exerts its transcriptional control via TEAD-mediated activation of enhancers. Plus Genet. 2015;11:e1005465.

Guo L, Chen Y, Luo J, Zheng J, Shao G. YAP1 overexpression is associated with poor prognosis of breast cancer patients and induces breast cancer cell growth by inhibiting PTEN. FEBS Open Bio. 2019;9:437–45.

Werneburg N, Groes GJ, Smoot RL. The Hippo pathway and YAP signaling: emerging concepts in regulation, signaling, and experimental targeting strategies with implications for hepatobiliary malignancies. Gene Expr. 2019. https://doi.org/10.13727/105221619X1561732483639.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of the NCIEWGqCD: REporting recommenda‑tions for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93:387–91.

Uhlen M, Zhang C, Lee S, Jostedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edscrews F, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:eaan2507.

The Human Protein Atlas. http://www.proteinatlas.org/pathology. Accessed 20 Jan 2020.

The Cancer Genome Atlas Program. https://www.cancer.gov/tcga. Accessed 20 Jan 2020.

Hu D, Amsal D, Zhou Q, Sasor A, Hilmersson KS, Bauden M, Jiang Y, Andersson R. Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma. BMC Cancer. 2018;18:1096.

Ishibashi H, Suzuki T, Suzuki S, Mortya T, Kaneko C, Takizawa T, Sunamori M, Handa K, Kondo T, Sasano H. Sex steroid hormone receptors in human thymoma. J Clin Endocrinol Metab. 2003;93:387–91.

John T, Liu G, Tsao MS. Overview of molecular testing in non‑small‑cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene. 2003;22:2309–17.

Chu CY, Chang CC, Prakash E, Kuo ML. Connective tissue growth factor (CTGF) and cancer progression. J Biomed Sci. 2008;15:675–85.

Ding L, Liu T, Wu Z, Hu B, Nakashima T, Ullenbruch M, Gonzalez De Los Santos F, Phan SH. Bone marrow CD11c+ cell-derived amphiregulin promotes pulmonary fibrosis. J Immunol. 2016;197:303–12.

Kurundkar AR, Kurundkar D, Rangarajan S, Locy ML, Zhou Y, Liu RM, Zmijewski J, Thannickal VJ. The matricellular protein CCN1 enhances TGF-beta1/SMAD3-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to lung injury. FASEB J. 2016;30:2135–50.

Li JT, Liao ZX, Ping J, Xu D, Wang H. Molecular mechanism of hepatocellular carcinoma: new insights into tumour development and treatment. Gene. 2008;43:419–28.

Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9:454–67.

Neesse A, Alghul H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64:1476–84.

Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlafmpecht MD, Mouw JK, et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med. 2016;22:497–505.

Zhan HX, Zhou B, Cheng YG, Xu JW, Wang L, Zhang Y, Hu SY. Crosstalk between stromal cells and cancer cells in pancreatic cancer: new insights into stromal biology. Cancer Lett. 2017;392:83–93.

Dupont S. Role of YAP/TAZ in cell-matrix adhesion-mediated signalling and mechanotransduction. Exp Cell Res. 2016;345:42–53.

Kim MK, Jang JW, Bae SC. DNA binding partners of YAP/TAZ. BMB Rep. 2018;51:126–33.

Choi HJ, Zhang H, Park H, Choi KS, Lee HW, Agrawal V, Kim YM, Kwon YG. Yes-associated protein regulates endothelial cell contact-mediated expression of angioptinin-2. Nat Commun. 2015;6:6943.

Jia J, Li C, Yang J, Wang X, Li R, Luo S, Li Z, Liu J, Liu Z, Zheng Y. Yes-associated protein promotes the abnormal proliferation of psoriatic keratinocytes via an amphiregulin dependent pathway. Sci Rep. 2018;8:14513.

Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnayyan AM, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22:11962–71.

Hudt LB, Brody JR, Gallmeier E, Iacobuzio-Danahue CA, Farrance IK, Kern SE. High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. Cancer Res. 2007;67:9055–66.

Koorntz LW, Liu-Chittenden Y, Yin F, Zheng Y, Yu J, Huang B, Chen Q, Wu S, Fan D. The Hippo effector Yorke controls normal tissue growth by antagonizing scalloped-mediated default repression. Dev Cell. 2013;25:388–401.

Ren YR, Patel K, Paun BC, Kern SE. Structural analysis of the cancer-specific promoter in mesothelin and in other genes overexpressed in cancers. J Biol Chem. 2011;286:11960–9.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.